Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Candel Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 25 | 21 | −4 |
| Shares | 6.08M | 5.42M | −660.5K (−10.9%) |
| Value | $19.1M | $9.70M | −$9.40M (−49.2%) |
New holders (2)
Institutions that held Candel Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ergoteles LLC | 26,114 | $46.7K | 0.00% |
| Jane Street Group, LLC | 13,425 | $24.0K | 0.00% |
Sold out (6)
Institutions that held Candel Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Point72 Asset Management, L.P. | 403,131 | $1.27M |
| Citadel Advisors LLC | 16,851 | $53.0K |
| Millennium Management LLC | 14,844 | $47.0K |
| Kestra Advisory Services, LLC | 12,500 | $39.0K |
| BNP Paribas Arbitrage, SA | 410 | $1.29K |
| China Universal Asset Management Co., Ltd. | 271 | $1.00K |